Attitudes toward opioid use disorder pharmacotherapy among recovery community center attendees

被引:11
|
作者
Hoffman, Lauren A.
Vilsaint, Corrie L.
Kelly, John F.
机构
[1] Massachusetts Gen Hosp, Recovery Res Inst, 151 Merrimac St, Boston, MA 02114 USA
[2] Harvard Med Sch, 151 Merrimac St, Boston, MA 02114 USA
关键词
Recovery community centers; Opioid use disorder; Buprenorphine; Methadone; Naltrexone; Addiction recovery; SUBSTANCE-ABUSE TREATMENT; ADDICTION TREATMENT; UNITED-STATES; SPIRITUALITY; MEDICATIONS; DRUG; VALIDATION; MEDICINE; ALCOHOL; SUPPORT;
D O I
10.1016/j.jsat.2021.108464
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Despite their proven efficacy, medications for opioid use disorder (MOUD) are underutilized. Negative beliefs and attitudes toward MOUD are quite common, yet rapidly expanding recovery community centers (RCCs) may offer a promising venue for fostering MOUD support as they operate under the maxim, "many pathways [to recovery], all should be celebrated" and are utilized mainly by those with opioid use disorder. The current study provides a first look at MOUD attitudes and their correlates in RCC attendees. Methods: The study conducted a cross-sectional survey (N = 320) of recovering adults attending 31 RCCs across New England, assessing demographic, treatment, and recovery-relevant factors, as well attitudes (positive vs. negative) toward the use of agonist and antagonist MOUD. The study used frequencies and confidence intervals to obtain prevalence estimates for positive and negative attitudes toward agonist and antagonist MOUD, and to examine differences between them. Spearman correlations identified correlates of MOUD attitudes (at p < 0.10), and significant correlates were assessed for unique contributions via multivariable logistic regression. Results: Positive attitudes were common and more prevalent than negative attitudes for both agonist (positive: 71.4 [66.1, 76.3]%; negative: 28.6 [23.7, 33.9]%) and antagonist (positive: 76.5 [71.4, 81.1]%; negative: 23.5 [18.9, 28.6]%) MOUD, which did not differ. The study identified several correlates of MOUD attitudes at the p < 0.10 level, but only four variables emerged as unique predictors controlling for other correlates. Lifetime history of agonist MOUD treatment was uniquely associated with positive agonist attitudes (p = 0.008), whereas greater social support for recovery was associated with positive antagonist attitudes (p = 0.007). Lower educational attainment was uniquely associated with negative antagonist attitudes (p = 0.005), and a greater degree of spirituality was related to negative attitudes toward both agonists (p = 0.005) and antagonists (p = 0.01). Conclusions: Findings reveal very high rates of positive MOUD attitudes among RCC participants, highlighting the potential for this growing tier of recovery support to foster acceptance and peer support for medication facilitated recovery pathways. Correlates of attitudes further reveal opportunities for facilitating MOUD acceptance within and beyond the RCC network.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Use and perceptions of Cannabidiol among individuals in treatment for opioid use disorder
    Kudrich, Christopher
    Chen, Rebecca
    Meng, Yuan
    Bachi, Keren
    Hurd, Yasmin L.
    HARM REDUCTION JOURNAL, 2024, 21 (01)
  • [42] Mobile treatment for opioid use disorder: Implementation of community-based, same-day medication access interventions
    Chatterjee, Avik
    Baker, Trevor
    Rudorf, Maria
    Walt, Galya
    Stotz, Caroline
    Martin, Anna
    Kinnard, Elizabeth N.
    McAlearney, Ann Scheck
    Bosak, Julie
    Medley, Bethany
    Pinkhover, Allyson
    Taylor, Jessica L.
    Samet, Jeffrey H.
    Lunze, Karsten
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 159
  • [43] Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science
    Finlay, Andrea K.
    Binswanger, Ingrid A.
    Timko, Christine
    Smelson, David
    Stimmel, Matthew A.
    Yu, Mengfei
    Bowe, Tom
    Harris, Alex H. S.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2018, 95 : 43 - 47
  • [44] Medications for Opioid Use Disorder and Mortality and Hospitalization Among People With Opioid Use-related Infections
    Figgatt, Mary C.
    Hincapie-Castillo, Juan M.
    Schranz, Asher J.
    Dasgupta, Nabarun
    Edwards, Jessie K.
    Jackson, Bradford E.
    Marshall, Stephen W.
    Golightly, Yvonne M.
    EPIDEMIOLOGY, 2024, 35 (01) : 7 - 15
  • [45] Evaluating attitudes among healthcare graduate students following interprofessional education on opioid use disorder
    Karagiannis, Chrissa
    Liang, Julia
    Pierre, Susan St.
    Brody, Carinne
    Kinnevey, Christina
    JOURNAL OF OSTEOPATHIC MEDICINE, 2024, 124 (02): : 85 - 93
  • [46] Treatment access for opioid use disorder in pregnancy among rural and American Indian communities
    Kelley, A. Taylor
    Smid, Marcela C.
    Baylis, Jacob D.
    Charron, Elizabeth
    Begaye, Lori Jo
    Binns-Calvey, Amy
    Archer, Shayla
    Weiner, Saul
    Pettey, Warren
    Cochran, Gerald
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2022, 136
  • [47] Gender differences among persons entering medication treatment for opioid use disorder in the community
    Di Paola, Angela
    Taweh, Noor
    Biondi, Breanne E.
    Foray, Ariadna
    Frank, Cynthia A.
    Shaw, Albert
    Springer, Sandra A.
    AMERICAN JOURNAL ON ADDICTIONS, 2022, 31 (05) : 390 - 395
  • [48] An examination of correlates of simultaneous opioid and benzodiazepine use among patients in medication treatment for opioid use disorder in a small midwestern community
    Ellis, Jennifer D.
    Pasman, Emily
    Brown, Suzanne
    Lister, Jamey J.
    Agius, Elizabeth
    Resko, Stella M.
    JOURNAL OF ADDICTIVE DISEASES, 2022, 40 (04) : 542 - 551
  • [49] Perceptions around medications for opioid use disorder among a diverse sample of US adults
    Jaffe, Kaitlyn
    Slat, Stephanie
    Chen, Liying
    Macleod, Colin
    Bohnert, Amy
    Lagisetty, Pooja
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 163
  • [50] Buprenorphine/Naloxone for Opioid Use Disorder Among Alaska Native and American Indian People
    Lillie, Kate M.
    Shaw, Jennifer
    Jansen, Kelley J.
    Garrison, Michelle M.
    JOURNAL OF ADDICTION MEDICINE, 2021, 15 (04) : 297 - 302